-TOYOPEARL填料在血浆蛋白中的应用.ppt

血液制品层析工艺中血液制品层析工艺中TOYOPEARL填料填料东曹东曹(TOSOH)公司公司生命科学部门生命科学部门.nPlasma Products ReviewnApplication on Plasma ProteinContent2.ProteinConcentration in PlasmaIndicationAlbumin40 g/LVolume restoration after trauma,shock,burnsAlpha1 Proteinase Inhibitor1.5 mg/mLHereditary emphysemaAnti-D IgGTiter variesaRh prophylaxis in pregnancy and childbirthAntithrombin III100 ug/mLAntithrombin III deficiencyC1-inhibitor170 ug/mLHereditary angioedemaFactor IX10 ug/mLHemophilia BFactor VIII0.5 ug/mLFactor VII deficiencyFactor XI0.3 ug/mLHemophilia BFactor XIII30 ug/mLFactor XIII deficiencyFibrinogen3 g/LTissue sealant componentFibronectin300 ug/mLWound healingHepatitis B IgGTiter variesaHepatitis immunityImmunoglobulin GUp to 12.5 g/LPrimary and secondary immune deficiencyMeasles IgGTiter variesaMeasles protection and treatmentProtein C4 ug/mLNeonatal thrombosisRabies IgGTiter variesaRabies riskTetanus IgGTiter variesaTetanus protection and treatmentThrombin150 ug/mLbTissue sealant componentVaricella Zoster IgGTiter variesaChicken pox protectionVon Willebrand Factor10 ugVon Willebrands diseaseaTiters(antibody concentrations)vary in ug/mL ranges.bAs prothrombinPlasma Proteins of Current Interest3.Plasma Products in China4.PlasmaprecipitationsupernatantCryoprecipitateFactor VIIIFraction ICentrifugation 4oCEthanol treatment,CentrifugationsupernatantprecipitationFibrinogenFactor IXAbtithrombin IIICohn Cold Ethanol Fractionation Process(Continued)5.precipitationsupernatantFraction IVFraction VEthanol treatment,CentrifugationsupernatantprecipitationHaptoglobinAbtithrombin IIIAlbuminFraction II+IIIsupernatantprecipitationprecipitationEthanol treatment,CentrifugationFraction IIGlobulin(for intramuscular)Globulin(for intravenous)Ethanol treatmentEthanol treatment,CentrifugationCohn Cold Ethanol Fractionation Process6.Production Capacity of Plasma ProteinsCapacity;Million L/YCompanies with yellow bar have applied Toyopearl to their process.7.CSL Bioplasma,AustralianCommonwealth Serum Laboratory(CSL)nInternational pharmaceutical company based in Australia as CSL groupsnAll processes were applied by chromatography for Cohn ethanol fractionation except Fraction 1 in 1994nThe fourth largest supplier of plasma proteins(2002)nGlobal company with manufacturing plant in US and Europe as well.nConsultant to Chinese plasma protein suppliers8.Why CSL Bioplasma Applies Chromatography?nCSL Bioplasma describes chromatography as;Highly cost effective process High production efficiency(IVIG;5.5 g/L)High quality(Albumin;99%w/v)Achievable of automatic,closed-processEasy extraction and separation of by-products (i.e.other plasma proteins)Advanced technique in bio-industry9.Production Process for Plasma ProteinsnSize Exclusion ChromatographyHW-55FnIon-Exchange ChromatographyDEAE-650M,QAE-550C,SuperQ-650S,MSP-650M,SP-550CnHydrophobic Interaction ChromatographyButyl-650M,C,Phenyl-650S,MnAffinity ChromatographyAF-Formyl 650M,AF-Heparin HC 650M10.Application of Plasma Products11.Purification of Albumin12.Purification of Albumin by AIECConditionColumn:ToyoScreen SuperQ-650M(1mL)Eluent:(A)50 mM Tris-HCl (B)50 mM Tris-HCl+0.5M NaClGradient:(A)-(B)Linear 30minFlow rate:1mL/minDetection:UV(280nm)Sample:Human Albumin,Globulin 1g/LInjection:100uL13.Purification of Albumin by CIECConditionColumn:ToyoScreen SP-650M(1mL)Eluent:(A)50 mM Acetic buffer(pH5.0)(B)50 mM Acetic buffer +0.5M NaCl(pH5.0)Gradient:(A)-(B)Linear 30minFlow rate:1mL/minSample:Human Albumin,Globulin 1g/LInjection:100uL14.Anion exchangerCation exchangerAlbuminGlobulinFraction VLoadingElutionLoadingElutionConsideration of Albumin Purification15.nChromatography in plasma fractionation:benefit and future trends T.Burnouf,J.Chromatgr.B 664(1995)3-15.“TOYOPEARL DEAE-650M is used to produce a highly purified FVIII concentrate,.”Purification of Factor VIII16.nStarting from Cohn fractionation,chromatography on TOYOPEARL DEAE-650M results in a highly purified clotting factor for treatment of hemophilia A.nMethod is licensed from Octapharma and includes two virus inactivation steps:solvent/detergent and heating.nScale is hundreds of million units per year.nTOYOPEARL DEAE-650M chromatography is the resin of choice.Purification of Factor VIII(Octanate)17.18.Condition Column size:6.0mmID*4cmL(1.13ml)Mobile phase :Loading:0.4mg/ml AT-III in 0.01M Tris-HCl containing 0.15M NaCl pH7.5 Linear Velocity:300cm/min Detection :UV(280nm)Resin AT-III binding capacity (10%leakage,mg/ml-gel)New Heparin-650M3.9Heparin Sepharose 6FF2.4Heparin-650M1.9Figure 1 Comparison of break through curve at 300cm/hComparison of dynamicAT-III binding capacity at 300cm/hPurification of AT-III19.Condition column size :6.0mmID*4cmL(1.13ml)Mobile phase :Loading:0.4mg/ml AT-III in 0.01M Tris-HCl containing 0.15M NaCl pH7.5 Detection :UV(280nm)Comparison of dynamic binding capacityPurification of AT-III20.Peak APeak Bbuffer Abuffer BAT-III Purification of AT-III from human plasma on Heparin-Toyopearl 650M Column size:6.0 mm I.D.X 4.0 cm Sample:Human plasma 18 ml Buffers:Adsorption,0.02 M Citrate+0.12 M NaCl (pH 7.2)Elution buffer A,0.02 M Citrate+0.4 M NaCl(pH 7.2)Elution buffer B,0.02M Citrate+2.0 M NaCl(pH 7.2)Flow rate:0.5 ml/min Temp.25 Detection:UV(280 nm)Purification of AT-III21.此课件下载可自行编辑修改，供参考！感谢您的支持，我们努力做得更好！